Rheumatic Disorders Drug Market By Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying antirheumatic Drugs (DMARDs), Corticosteroids, Uric Acid Drugs, Biologic Response Modifiers), By Disease Indication (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylo

Rheumatic Disorders Drug Market Valuation – 2024-2031

Rheumatic Disorders Drug Market size was valued at USD 71.48 Billion in 2024 and is projected to reach USD 106.74 Billion by 2031, growing at a CAGR of 5.14% from 2024 to 2031.

This significant market value is underpinned by various influential factors, including the widespread prevalence of rheumatic diseases, continuous advancements in treatment modalities, and the competitive landscape within the industry.

Rheumatic Disorders Drug Market Definition / Overview

Rheumatic disorders encompass a broad spectrum of conditions, ranging from rheumatoid arthritis and lupus to osteoarthritis and gout. These ailments impose considerable burdens on patients globally, necessitating effective pharmacological interventions to alleviate symptoms and manage disease progression. As a result, the market for drugs targeting rheumatic disorders commands substantial attention and investment.

The rheumatic disorder drug is primarily medication used to reduce the pain and progression of this disease as it may result in complete dysfunctionality and movement of the joints, connective tissue, ligaments, tendons, cartilage, bone, and muscle. The majority of rheumatic disorders are treated using largely genericized pain management drugs, creating a better scope for the market.

According to the American College of Rheumatology and the Arthritis Foundation (ACR/AF), NSAIDs are amongst the effective OTC remedies to manage pain related to osteoarthritis (OA). Some of them include ibuprofen (Motrin) tablets for every type of OA, creams, and ointments that contain NSAIDs for OA of the hand and knee. The other NSAIDs approved by the American Academy of Orthopaedic Surgeons (AAOS) are naproxen (Aleve), aspirin, and nabumetone (Refalen).

Will Susceptibility of Aging Population Drive the Rheumatic Disorders Drug Market?

Despite existing treatments, many patients are still experiencing unmet needs in terms of symptom control, disease progression, and long-term outcomes. This is creating demand for improved and innovative therapeutics, fueling market expansion.

Unhealthy or sedentary lifestyle factors are leading to obesity due to physical inactivity and this is contributing to the rise of some rheumatic disorders. In addition to this, the rise in global aging population is leading to an increase in risk of age-related rheumatic disorders like osteoarthritis and rheumatoid arthritis. All these factors are stirring up the sales of rheumatic disorders drug over the forecast period.

Growing awareness about rheumatic disorders and improved diagnostic tools lead to earlier diagnoses and treatment initiation, boosting demand for associated medications. Expanding access to healthcare in developing countries opens up new markets for rheumatic disorder drugs, further propelling market growth.

With the growing effort of regulatory agencies in streamlining approval processes for innovative drugs addressing unmet needs, potentially reducing time to market and government initiatives supporting research are a boon for the market.

Furthermore, technological advancements like genomics, bioinformatics, and artificial intelligence in the field of healthcare are accelerating drug discovery and development. It is projected to help develop biologic drugs, targeted drugs, and other personalized treatment options, and fuel the growth of the market over a limited timeframe.

Will High Cost of Rheumatic Drugs Plummet its Sales Over the Forecast Period?

High requirement of large patient populations and long durations when conducting clinical trials for complex rheumatic disorders is likely to upfront the expenses. This financial expenditure is anticipated to limit its adoption by the smaller enterprises facing budget constraints, potentially hindering innovation and diversity in treatment options.

High prices of the drug as well as the development costs are projected to restrain its application in the developing or poor regions with limited healthcare coverage. Also, the unfavorable reimbursement policies restricts patients access to innovative rheumatic drugs.

While stringent regulations might upkeep the safety and efficiency of new drugs, their lengthy and complex clinical trials and approval processes is hindering the adoption of the rheumatic disorders drug.

Furthermore, despite growing awareness and unmet medical needs, funding for research and development of new treatments for rheumatic disorders can be limited compared to other major disease areas.

Category-Wise Acumens

How will Sales of DMARDs Impact the Rheumatic Disorders Drug Market?

As per our analyst, disease-modifying antirheumatic drugs (DMARDs) are anticipated to dominate the Rheumatic Disorders Drug Market over the forecast period.

The increase in the emergence of rheumatic disorders among all age groups, especially the geriatric populace, is bolstering the demand for inexpensive and well-established safety profile drugs. Also, the demand for minimally invasive treatments such as oral administration is likely to open new paths for the expansion for the DMARDs.

The ease and reactiveness in suppressing the overactive immune system contributing to inflammation and joint damage in rheumatic disorders will further enhance the demand for DMARDs.

However, the market is witnessing a shift towards biologic drugs due to their targeted mechanisms of action and potential for improved efficacy and safety profiles.

Which Distribution Channel Offers Easy Accessibility to Rheumatic Disorders Drugs?

The retail segment is projected to hold ~60-70% of the market share due to wider reach and accessibility for OTC and some prescription drugs.

The high prevalence of rheumatic disorders causing excruciating pain is increasing the demand for easy accessibility to the necessary painkillers from nearby sources, thereby widening the need for retail outlets.

Also, the easy availability of over-the-counter drugs or few specialized drugs in the retail stores with established relationships with healthcare providers and insurance companies. Likewise, the option of price negotiation is influencing patient choice, offering immense opportunities for the retail stores.

Gain Access into Rheumatic Disorders Drug Market Methodology

Country/Region-wise Acumens

How will Sales of Rheumatic Disorders Drug Fare in North America?

According to the latest Rheumatic Disorders Drug Market analysis, North America is expected to hold largest share from 2023 to 2031. Changing lifestyle that is physical inactivity or sedentary factors are leading to the emergence of osteoarthritis and rheumatoid arthritis in the region. High prevalence of this disease is projected to enhance the growth of the market in North America.

The constant research as well as early adoption of monoclonal antibodies to combat the prevalent rheumatoid arthritis are propelling the demand for rheumatoid arthritis drugs in this region.

According to the CDC, more than 58 million people in the U.S. suffer from arthritis. As per the Government of Canada, as of September 2020, close to 374,000 people in Canada aged 16 and above suffered from rheumatoid arthritis.

Moreover, the high disposable income and government support is helping the patients prefer biologics and personalized medicine, prompting higher demand for Rheumatic Disorders Drug Market.

Will Asia Pacific Become Epicenter of Growth for the Market?

Asia Pacific is estimated to experience highest growth over the forecast period. The factor majorly attributable for the growth is the increase in aging population susceptible to various diseases in the developing as well as heavily populated countries including China, India, South Korea, and Japan.

According to the Asian Development Bank, by 2050, one in four people in Asia Pacific is expected to be over 60 years old. The population of older persons (aged over 60) in the region is projected to triple between 2010 and 2050, reaching close to 1.3 billion people.

Also, the rise in middle class or bankruptcy in the developing countries in Asia Pacific is compelling the government and healthcare organizations to invest in rheumatic disorder drugs clinical trials to develop cost-effective, and efficient biosimilars. This constant research and development in the field of rheumatology is bolstering the growth of market.

Competitive Landscape

The competitive landscape of the Rheumatic Disorders Drug Market is diverse and dynamic. The players are expanding portfolios and adopting new strategies such as mergers & acquisitions, and regional partnerships to add innovative biologics, and targeted therapies into their pipeline.

Some of the prominent players operating in the Rheumatic Disorders Drug Market include

AbbVie, Amgen, Novartis, Pfizer Roche/Genentech, Johnson & Johnson, Bristol Myers Squibb, Eli Lilly, UCB, Gilead Sciences, Merck, Cipla, Sun Pharma, Hikma Pharmaceuticals, Sinopharm, F. Hoffmann-La Roche Ltd.

Latest Developments

• In January 2023, AbbVie and Galapagos introduced positive Phase 3 results for filgotinib in psoriatic arthritis. This will help AbbVie retain its position in the JAK inhibitor market for rheumatic disorders.
• In January 2023, Roche receives FDA approval for Gavopi™ (efgartigimod alpha) for chronic inflammatory demyelinating polyneuropathy (CIDP). This development will expand Roche’s portfolio into a niche but growing market.
• In March 2023, Eli Lilly receives FDA approval for Olumiant® (baricitinib) in active non-radiographic axial spondyloarthritis (nr-axSpA). This expands the range of conditions for which baricitinib is approved.
• In February 2024, GlaxoSmithKline (GSK) declared collaboration with iTeos Therapeutics to produce and market T-cell receptor (TCR) therapies for autoimmune diseases, including several rheumatic disorders. This reflects the growing interest in novel immunotherapies.

Rheumatic Disorders Drug Market, Segmentation Analysis

The Global Rheumatic Disorders Drug Market is Segmented on the Basis of Drug Class, Disease Indication, Distribution Channel And Geography.

By Drug Class

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Disease-Modifying Antirheumatic Drugs (DMARDs)
• Corticosteroids
• Uric Acid Drugs
• Biologic Response Modifiers

By Disease Indication

• Rheumatoid Arthritis
• Osteoarthritis
• Gout
• Psoriatic Arthritis
• Ankylosing Spondylitis

By Distribution Channel

• Hospital
• Retail
• Online

By Geography

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Report Scope

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

In case of any please connect with our sales team, who will ensure that your requirements are met.